Basic Research

RVM neuronsHeinricher laboratory

Dr. Heinricher's laboratory investigates brainstem mechanisms involved in pain modulation. Their focus is on opioid-sensitive circuits within the rostral ventral medulla (RVM), which is a crucial element in a pain-modulating network with links in the midbrain, medulla and spinal cord. This network contributes to the variability in pain sensitivity seen in different situations (for example under conditions of fear or extreme stress), and it is an important substrate for opioids and other analgesic drugs such as cannabinoids. The laboratory uses single cell recording in combination with pharmacological tools to analyze how this system is activated, and they have identified two distinct classes of pain modulating neurons.

  • ON cells are directly sensitive to opioids, and they recently showed that these neurons facilitate nociceptive transmission.
  • OFF-cells exert a net inhibitory effect on nociception, and they were able to demonstrate that disinhibition of these neurons is central to the antinociceptive actions of opioids within the medulla.

Currently, they are interested in identifying neurotransmitters that activate these two cell classes differentially to promote or suppress pain. They are also interested in how this modulatory system is activated under physiological conditions, and are looking at the inputs from limbic forebrain structures such as the hypothalamus to the rostral ventral medulla in an attempt to investigate this issue.

Anderson laboratory

Abnormal movement of water into and out of the brain plays a key role in many neurodegenerative disorders. Dr. Anderson's laboratory is focused on the application of high-field magnetic resonance techniques to the study of water permeability and the vascular microenvironment of Alzheimer's disease.

Morrison laboratory

Specific circuits within the CNS are dedicated to the maintenance of homeostasis and an optimal cellular environment through regulation of autonomic function. Disease states such as fever, obesity, diabetes, hypertension, autonomic hyperreflexia and cardiac arrhythmia are associated with altered regulation of the sympathetic outflow to cardiovascular and non-cardiovascular tissues.

Dr. Morrison's laboratory research uses electrophysiological and anatomical approaches to understand the functional organization, rhythmicities, developmental influences and pharmacology of the CNS circuits that regulate the sympathetic outflows controlling variables critical for homeostasis such as body temperature, energy expenditure, blood glucose, blood pressure, cardiac output and plasma catecholamines.

Selden laboratory

Dr. Selden's laboratory investigates the mechanisms involved in control of chronic pain. Chronic pain is a ubiquitous, debilitating and costly affliction of both children and adults.  Important aspects of pain-related behavior are mediated by supraspinal mechanisms.  The rostral ventromedial medulla (RVM) has both anti- and pro-nociceptive modulatory capabilities, each referable to a distinct, physiologically identified cell class.  OFF-cells are proposed to inhibit, and ON-cells to facilitate, nociceptive processing.  The remaining RVM neurons, NEUTRAL-cells, do not alter their activity in relationship to nocifensive behavior, and their role in pain modulation is currently unclear.  His research employs complementary electrophysiological and anatomical approaches (single cell recording and iontophoresis, juxtacellular labeling, and immunohistochemistry) to characterize the distribution of purinergic receptors on the three cell classes. 

Cetas laboratory

The major focus of Dr. Cetas's laboratory is to understand the effects of subarachnoid hemorrhage on the brainstem and central nervous system and their subsequent role in determining long-term outcomes.

Delayed vasospasm is a common and devastating consequence of subarachnoid hemorrhage (SAH) that is poorly understood with few effective treatments. The aim of Dr. Cetas's laboratory research is to identify a novel biomarker for predicting a patient's risk for developing delayed vasospasm and subsequent neurological deficits, as well as a new potential therapeutic target for the medical prevention of delayed vasospasm. Specifically, preliminary data both in animal models and patients of SAH suggest that a group of potent vasodilator metabolites of arachidonic acid (called epoxyeicosatrienoic acids or simply EETs) are linked to the development of vasospasm and may predict its development after SAH. The reasearchers propose to test the hypothesis that EETs levels after SAH correlate with the development of delayed vasospasm and that polymorphisms in the gene EPHX2 (which regulates the metabolism of EETs) correlate with an individual’s EETs response. They anticipate that individuals whose EETs levels are elevated after SAH will not go on to develop vasospasm. Furthermore, they predict that those individuals who do not elevate their EETs levels after SAH will have a higher frequency of polymorphisms in the EPHX2 gene.